Trisenox Related Published Studies
Well-designed clinical trials related to Trisenox (Arsenic Trioxide)
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. [2007.03.15]
[Clinical observation and following up of two administration methods of arsenic trioxide in treatment of acute promyelocytic leukemia] [2004.03.02]
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. [2003.06.15]
[An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid] [1999.02]
Well-designed clinical trials possibly related to Trisenox (Arsenic Trioxide)
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. [2004.04.13]
Other research related to Trisenox (Arsenic Trioxide)
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. [2008.11.01]
Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. [2008.11]
Role of p38 MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation. [2008.09]
Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine. [2008.08.31]
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. [2008.08]
Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. [2008.08]
Evaluation of arsenic trioxide-loaded albumin nanoparticles as carriers: preparation and antitumor efficacy. [2008.08]
Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. [2008.08]
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. [2008.07.31]
All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. [2008.07]
Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone. [2008.07]
Arsenic trioxide. [2008.07]
Mandibular bone necrosis caused by use of arsenic paste during endodontic treatment: two case reports. [2008.07]
Hyperleukocytosis from arsenic trioxide. [2008.06]
Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia. [2008.05.15]
Arsenic trioxide-induced apoptosis in H9c2 cardiomyocytes: implications in cardiotoxicity. [2008.05]
Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide. [2008.04]
Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains. [2008.04]
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. [2008.04]
Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. [2008.03.01]
Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. [2008.02]
Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses. [2008.01.25]
Analytical artefacts in the speciation of arsenic in clinical samples. [2008.01.21]
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. [2008.01.15]
Comparative efficacy of two microdoses of a potentized homeopathic drug, arsenicum album, to ameliorate toxicity induced by repeated sublethal injections of arsenic trioxide in mice. [2008]
Insight into the selectivity of arsenic trioxide for acute promyelocytic leukemia cells by characterizing Saccharomyces cerevisiae deletion strains that are sensitive or resistant to the metalloid. [2008]
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. [2007.12.12]
Gene-mutation induction by arsenic compounds in the mouse lymphoma assay. [2007.12.01]
Using targeted magnetic arsenic trioxide nanoparticles for osteosarcoma treatment. [2007.12]
New data with arsenic trioxide in leukemias and myelodysplastic syndromes. [2007.12]
[Successful cyclosporine treatment for thrombocytopenia after salvage therapy with arsenic trioxide therapy followed by autologous hematopoietic stem cell transplantation in acute promyelocytic leukemia] [2007.12]
Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. [2007.11]
[Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice] [2007.10]
Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. [2007.10]
PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. [2007.10]
Arsenical-based cancer drugs. [2007.10]
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. [2007.09.15]
A potentized homeopathic drug, Arsenicum Album 200, can ameliorate genotoxicity induced by repeated injections of arsenic trioxide in mice. [2007.09]
[Relationship between radiotherapy enhancing effect of arsenic trioxide and the proliferation and apoptosis of related protein in nasopharyngeal carcinoma patients] [2007.08]
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. [2007.08]
PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells. [2007.08]
Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. [2007.07]
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. [2007.06.29]
[Organoarsenicals derived from 2-phenyl-[1,3,2]dithiarsolan-4-yl)-methanol (AsIII) with antileukaemic properties: from trypanosomicides to anticancer drugs] [2007.05]
Arsenic-induced APL differentiation in cerebrospinal fluid. [2007.05]
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. [2007.04.01]
Osteomyelitis due to arsenic trioxide use for tooth devitalization. [2007.04]
Therapeutic effect of arsenic trioxide (As2O3) on cervical cancer in vitro and in vivo through apoptosis induction. [2007.04]
Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. [2007.03]
Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. [2007.03]
Synergistic therapeutic effect of arsenic trioxide and radiotherapy in BALB/C nude mice bearing nasopharyngeal carcinoma xenografts. [2007.03]
[Effects of controlled-release arsenic-trioxide-eluting stents on in-stent neointimal hyperplasia in coronary artery: experiment with dog model] [2007.02.27]
[Effects of controlled-release arsenic-trioxide-eluting stents on in-stent neointimal hyperplasia in coronary artery: experiment with dog model.] [2007.02.20]
Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. [2007.02]
[Effects of arsenic trioxide on the autoimmunity and survival time in BXSB lupus mice] [2007.02]
Arsenic trioxide and neuroblastoma cytotoxicity. [2007.02]
Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia. [2007.01]
Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells. [2007.01]
Arsenic trioxide and acute promyelocytic leukemia: clinical and biological. [2007]
A patient with progressive multiple myeloma treated successfully with arsenic trioxide after allogeneic bone marrow transplantation. [2007]
Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: A clinical experience. [2007]
Effect of arsenic trioxide on uveal melanoma cell proliferation in vitro. [2007]
[Two different clinical cases of acute arsenic trioxide intoxication] [2007]
Arsenic trioxide, a potent inhibitor of NF-kappaB, abrogates allergen-induced airway hyperresponsiveness and inflammation. [2006.12.20]
Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. [2006.12.15]
Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model. [2006.12.01]
Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. [2006.12]
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? [2006.12]
Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. [2006.11.15]
Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin. [2006.11.15]
Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? [2006.11]
Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles. [2006.11]
Effects of dietary arsenic levels on serum parameters and trace mineral retentions in growing and finishing pigs. [2006.11]
Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. [2006.11]
[Mechanisms of arsenic trioxide induced tumor cell apoptosis in myelodysplastic syndrome mice model in vivo] [2006.10]
Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication. [2006.10]
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. [2006.10]
Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy. [2006.10]
Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer. [2006.09.28]
Anion exchanger 2 mediates the action of arsenic trioxide. [2006.09]
Arsonoliposomes: novel nanosized arsenic-containing vesicles for drug delivery. [2006.09]
Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. [2006.09]
A phase I study to study arsenic trioxide with radiation and hyperthermia in advanced head and neck cancer. [2006.08]
A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia. [2006.08]
Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. [2006.08]
Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. [2006.07]
Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. [2006.07]
The efficacy of combined therapy of arsenic trioxide and alpha interferon in human T-cell leukemia virus type-1-infected squirrel monkeys (Saimiri sciureus). [2006.07]
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. [2006.06.15]
[Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma] [2006.06.15]
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. [2006.06.01]
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. [2006.06.01]
Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. [2006.06.01]
Effects of arsenic trioxide administration styles on leukocytosis. [2006.06]
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. [2006.05.01]
Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy. [2006.05]
|
